

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1805SXM

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08 "Ask CAS" for self-help around the clock
NEWS	3	Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09 ZDB will be removed from STN
NEWS	5	Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03 New e-mail delivery for search results now available
NEWS	10	Jun 10 MEDLINE Reload
NEWS	11	Jun 10 PCTFULL has been reloaded
NEWS	12	Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22 USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29 Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30 NETFIRST to be removed from STN
NEWS	16	Aug 08 CANCERLIT reload
NEWS	17	Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08 NTIS has been reloaded and enhanced
NEWS	19	Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26 Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03 JAPIO has been reloaded and enhanced
NEWS EXPRESS		February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:28:50 ON 11 SEP 2002

=> file medline caplus biotechno embase scisearch biosis		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'MEDLINE' ENTERED AT 14:30:23 ON 11 SEP 2002

FILE 'CAPLUS' ENTERED AT 14:30:23 ON 11 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 14:30:23 ON 11 SEP 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'EMBASE' ENTERED AT 14:30:23 ON 11 SEP 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 14:30:23 ON 11 SEP 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'BIOSIS' ENTERED AT 14:30:23 ON 11 SEP 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

=> s antisense or anti-sense
L1 110624 ANTISENSE OR ANTI-SENSE

=> s ribozyme#
L2 20913 RIBOZYME#

=> s hexokinase
L3 30260 HEXOKINASE

=> s l3 and type-I
L4 851 L3 AND TYPE-I

=> s l3 and type-1
L5 174 L3 AND TYPE-1

=> s l3 and type-II
L6 614 L3 AND TYPE-II

=> s l3 and type-2
L7 189 L3 AND TYPE-2

=> s l4 or l5 or l6 or l7
L8 1439 L4 OR L5 OR L6 OR L7

=> s l1 and l3
L9 62 L1 AND L3

=> ds l2 and l3
DS IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l2 and l3
L10 10 L2 AND L3

=> s l1 and l8
L11 7 L1 AND L8

=> dup rem l9
PROCESSING COMPLETED FOR L9
L12 33 DUP REM L9 (29 DUPLICATES REMOVED)

=> dup rem l10
PROCESSING COMPLETED FOR L10
L13 9 DUP REM L10 (1 DUPLICATE REMOVED)

=> dup rem l11
PROCESSING COMPLETED FOR L11
L14 5 DUP REM L11 (2 DUPLICATES REMOVED)

=> d 1-5 ti

L14 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2002 ACS
TI Large-scale monitoring of expression patterns of p53-regulated gene and analysis of p53 gene function

L14 ANSWER 2 OF 5 BIOTECHNO COPYRIGHT 2002 Elsevier Science B.V.DUPLICATE
TI Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: Applications to breast cancer

L14 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS
TI Cancer diagnosis and therapy based on expression levels of p53-regulated genes

L14 ANSWER 4 OF 5 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
TI Arrest of proliferation of highly glycolytic tumors upon **Type II hexokinase** down regulation via an **antisense** RNA approach.

L14 ANSWER 5 OF 5 BIOTECHNO COPYRIGHT 2002 Elsevier Science B.V.DUPLICATE
TI Ribozyme-mediated attenuation of pancreatic .beta.-cell glucokinase expression in transgenic mice results in impaired glucose-induced insulin secretion

=> d ab 4 5

L14 ANSWER 4 OF 5 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

L14 ANSWER 5 OF 5 BIOTECHNO COPYRIGHT 2002 Elsevier Science B.V.DUPLICATE
AB Phosphorylation of glucose to glucose 6-phosphate by glucokinase (GK; EC 2.7.1.2) serves as a glucose-sensing mechanism for regulating insulin secretion in .beta. cells. Recent findings of heterozygous GK gene mutations in patients with maturity-onset diabetes of the young (MODY), a form of **type II** (non-insulin-dependent) diabetes characterized by autosomal dominant inheritance, have raised the possibility that a decrease in .beta.-cell GK activity may impair the insulin secretory response of these cells to glucose. To generate an animal model for MODY we have expressed in transgenic mice a GK **antisense** RNA with a ribozyme element under control of the insulin promoter. Mice in two independent lineages had about 30% of the normal islet GK activity. Insulin release in response to glucose from in situ-perfused pancreas was impaired; however, the plasma glucose and insulin levels of the mice remained normal. These mice are likely to be predisposed to **type II** diabetes and may manifest increased susceptibility to genetic and environmental diabetogenic factors. They provide an animal model for studying the interaction of such factors with the reduced islet GK activity.

=> d 4

L14 ANSWER 4 OF 5 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:184331 BIOSIS
DN PREV199900184331
TI Arrest of proliferation of highly glycolytic tumors upon **Type II hexokinase** down regulation via an **antisense** RNA approach.
AU Mathupala, Saroj P.; Pedersen, Peter L.
CS Dep. Biol. Chem., Johns Hopkins Univ. Sch. Med., Baltimore, MD 21205 USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (March, 1999) Vol. 40, pp. 22.
Meeting Info.: 90th Annual Meeting of the American Association for Cancer Research Philadelphia, Pennsylvania, USA April 10-14, 1999 American Association for Cancer Research
. ISSN: 0197-016X.
DT Conference
LA English

=> d his

(FILE 'HOME' ENTERED AT 14:28:50 ON 11 SEP 2002)

FILE 'MEDLINE, CAPLUS, BIOTECHNO, EMBASE, SCISEARCH, BIOSIS' ENTERED AT 14:30:23 ON 11 SEP 2002

L1 110624 S ANTISENSE OR ANTI-SENSE
L2 20913 S RIBOZYME#
L3 30260 S HEXOKINASE
L4 851 S L3 AND TYPE-I
L5 174 S L3 AND TYPE-1
L6 614 S L3 AND TYPE-II
L7 189 S L3 AND TYPE-2
L8 1439 S L4 OR L5 OR L6 OR L7
L9 62 S L1 AND L3
L10 10 S L2 AND L3
L11 7 S L1 AND L8
L12 33 DUP REM L9 (29 DUPLICATES REMOVED)
L13 9 DUP REM L10 (1 DUPLICATE REMOVED)
L14 5 DUP REM L11 (2 DUPLICATES REMOVED)

=> s l13 not l14

L15 8 L13 NOT L14

=> d 1-8 ti

L15 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2002 ACS
TI Cloning, expression, sequence and therapeutic use of a novel human **hexokinase** 50365

L15 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2002 ACS
TI Method for influencing pollen development by modifying sucrose metabolism

L15 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2002 ACS
TI Engineering of replication selective adenoviruses with tumor-associated antigen promoter for use in cancer therapy

L15 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2002 ACS
TI Recombinant secretory cells and their use in production of human insulin

L15 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2002 ACS
TI Methods and compositions for inhibiting **hexokinase** in mammalian cells and their use for treating diabetes

L15 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2002 ACS
TI Neuroendocrine cell lines for efficient synthesis and secretion of foreign proteins

L15 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2002 ACS
TI Inhibitors of **hexokinase** function for increasing levels of synthesis of insulin in producer cells

L15 ANSWER 8 OF 8 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
TI Methods and compositions for inhibiting **hexokinase**.

=> d 3 8 ab

L15 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2002 ACS
AB The invention provides a replication selective adenovirus (Ad) mutant with improved selectivity for tumor cells expressing the tumor assocd. antigen in cancers and malignancies, as well as in proliferative cells, characterizing diseases, such as restenosis, intimal proliferative disease and pulmonary hypertension. The selected Ad vectors are driven by promoters of the tumor assocd. antigens, or RNA transcripts or genes therefor, substituting for the activity of at least adenovirus E1A promoter, which has been deactivated or diminished. Also provided is the use of the Ad vector to deliver therapeutic compns. to patients, as well as a method for treating cancers, such as CEA pos. cancers, or proliferative cell diseases in a patient by administering to the patient an effective amt. of the Ad vector, which may also express a therapeutic gene or peptide, and treatment may also be combined with radiation, chemotherapy or immunomodulatory agents. The Ad is designed to replicate within the tumor cell, thereby spreading throughout the tumor nodule. This permits the delivery of a much higher dose of the heterologous therapeutic protein than previously possible, and the virus achieves a direct, oncolytic effect on the tumor.

L15 ANSWER 8 OF 8 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AB Disclosed are compositions and methods for inhibiting **hexokinase** enzymes in mammalian cells. Specifically provided are proteins that stimulate the production of trehalose-6-phosphate and their respective genes; **hexokinase**-specific **ribozymes** and genes encoding such constructs; and agents that competitively reduce **hexokinase** activity, e.g., by displacing **hexokinase** from mitochondria, and their respective genes. The latter group of agents includes inactive hexokinases and fragments thereof that retain mitochondrial binding functions and **hexokinase**-glucokinase chimeras that further substitute glucokinase activity for **hexokinase** activity. Mammalian cells including such **hexokinase** inhibitors, methods of making such cells and various in vitro and in vivo methods of using cells with reduced **hexokinase** activity are also described herein.

=> d 3 8

L15 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2002 ACS
AN 2001:247215 CAPLUS
DN 134:276498
TI Engineering of replication selective adenoviruses with tumor-associated antigen promoter for use in cancer therapy
IN Molnar-kimber, Katherine; Toyozumi, Takane
PA The Trustees of the University of Pennsylvania, USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001023004	A1	20010405	WO 2000-US27212	20001002
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1999-157224P	P	19990930		
RE.CNT	7	THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L15 ANSWER 8 OF 8 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:305505 BIOSIS
DN PREV199900305505
TI Methods and compositions for inhibiting **hexokinase**.
AU Becker, Thomas C.; Han, He-Ping; Newgard, Christopher B. (1); Wilson, John E.
CS (1) University of Texas Southwestern Medical Center at Dallas, Dallas, TX USA
ASSIGNEE: Board of Regents, The University of Texas System
PI US 5891717
SO Official Gazette of the United States Patent and Trademark Office Patents, (15-JUN-99) Vol. 1221, No. 1, pp. NO PAGINATION.
ISSN: 0098-1133.
DT Patent
LA English

=> l12 not (l13 or l14)

L12 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> s l12 not (l13 or l14)

L16 24 L12 NOT (L13 OR L14)

=> d 1-24 ti

L16 ANSWER 1 OF 24 MEDLINE

TI Potato **hexokinase** 2 complements transgenic Arabidopsis plants deficient in **hexokinase** 1 but does not play a key role in tuber carbohydrate metabolism.

L16 ANSWER 2 OF 24 MEDLINE

TI The effect of exogenous sugars on the control of flux by adenosine 5'-diphosphoglucose pyrophosphorylase in potato tuber discs.

L16 ANSWER 3 OF 24 MEDLINE

TI Control of carbon partitioning and photosynthesis by the triose phosphate/phosphate translocator in transgenic tobacco plants (*Nicotiana tabacum* L.). I. Comparative physiological analysis of tobacco plants with **antisense** repression and overexpression of the triose phosphate/phosphate translocator.

L16 ANSWER 4 OF 24 MEDLINE

TI **Antisense** repression of **hexokinase** 1 leads to an overaccumulation of starch in leaves of transgenic potato plants but not

to significant changes in tuber carbohydrate metabolism.

- L16 ANSWER 5 OF 24 MEDLINE
TI Compensation of decreased triose phosphate/phosphate translocator activity by accelerated starch turnover and glucose transport in transgenic tobacco.
- L16 ANSWER 6 OF 24 MEDLINE
TI **Hexokinase** as a sugar sensor in higher plants.
- L16 ANSWER 7 OF 24 MEDLINE
TI Evidence of the crucial role of sucrose synthase for sink strength using transgenic potato plants (*Solanum tuberosum* L.).
- L16 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2002 ACS
TI Protein and cDNA sequences of a novel human **hexokinase** 14 and therapeutic use thereof
- L16 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2002 ACS
TI Protein and cDNA sequences of 11 kDa human **hexokinase**-like protein and therapeutic use thereof
- L16 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2002 ACS
TI Protein and cDNA sequences of 10 kDa human **hexokinase** sequence homolog and therapeutic use thereof
- L16 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2002 ACS
TI Arrest of proliferation of highly glycolytic tumors by **antisense** oligonucleotides of **hexokinase** cDNA
- L16 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2002 ACS
TI Protein and cDNA of 12 kDa human **hexokinase** sequence homolog and therapeutic use thereof
- L16 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2002 ACS
TI Moss genes from *Physcomitrella patens* encoding proteins involved in the synthesis of carbohydrates
- L16 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2002 ACS
TI Plant galactose dehydrogenase
- L16 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2002 ACS
TI Induction of the activity of glycolytic enzymes correlates with enhanced hydrolysis of sucrose in the cytosol of transgenic potato tubers
- L16 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2002 ACS
TI Altering plant responses to sugar concentrations by altering **hexokinase** concentrations
- L16 ANSWER 17 OF 24 BIOTECHNO COPYRIGHT 2002 Elsevier Science B.V.
TI Sucrose-starch conversion in heterotrophic tissues of plants
- L16 ANSWER 18 OF 24 SCISEARCH COPYRIGHT 2002 ISI (R)
TI Regulation of photosynthesis during *Arabidopsis* leaf development in continuous light
- L16 ANSWER 19 OF 24 SCISEARCH COPYRIGHT 2002 ISI (R)
TI Sucrose and light regulation of a cold-inducible UDP-glucose pyrophosphorylase gene via a **hexokinase**-independent and abscisic acid-insensitive pathway in *Arabidopsis*
- L16 ANSWER 20 OF 24 SCISEARCH COPYRIGHT 2002 ISI (R)
TI Alternative interpretations of the oligonucleotide transport literature: insights from nature

- L16 ANSWER 21 OF 24 SCISEARCH COPYRIGHT 2002 ISI (R)
TI **Antisense** oligonucleotides targeting malarial aldolase inhibit
the asexual erythrocytic stages of Plasmodium falciparum
- L16 ANSWER 22 OF 24 SCISEARCH COPYRIGHT 2002 ISI (R)
TI Developmental changes of enzymes involved in conversion of sucrose to
hexose-phosphate during early tuberisation of potato
- L16 ANSWER 23 OF 24 SCISEARCH COPYRIGHT 2002 ISI (R)
TI EXPRESSION OF OXIDATIVE-PHOSPHORYLATION GENES IN RENAL TUMORS AND TUMORAL
CELL-LINES
- L16 ANSWER 24 OF 24 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
TI Microarray analysis of PTP1B **antisense**-treated ob/ob mice
reveals downregulation of genes involved in the gluconeogenesis pathway.